Wasserberg Nir
Nir Wasserberg, Department of Surgery B, Rabin Medical Center, Beilinson Campus, Petach Tikva and Sackler School of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel.
World J Gastroenterol. 2014 Apr 21;20(15):4256-62. doi: 10.3748/wjg.v20.i15.4256.
The current standard treatment of low-lying locally advanced rectal cancer consists of chemoradiation followed by radical surgery. The interval between chemoradiation and surgery varied for many years until the 1999 Lyon R90-01 trial which compared the effects of a short (2-wk) and long (6-wk) interval. Results showed a better clinical tumor response (71.7% vs 53.1%) and higher rate of positive and pathologic tumor regression (26% vs 10.3%) after the longer interval. Accordingly, a 6-wk interval between chemoradiation and surgery was set to balance the oncological results with the surgical complexity. However, several recent retrospective studies reported that prolonging the interval beyond 8 or even 12 wk may lead to significantly higher rates of tumor downstaging and pathologic complete response. This in turn, according to some reports, may improve overall and disease-free survival, without increasing the surgical difficulty or complications. This work reviews the data on the effect of different intervals, derived mostly from retrospective analyses using a wide variation of treatment protocols. Prospective randomized trials are currently ongoing.
低位局部晚期直肠癌的当前标准治疗包括放化疗后行根治性手术。多年来,放化疗与手术之间的间隔时间各不相同,直到1999年的里昂R90 - 01试验,该试验比较了短间隔(2周)和长间隔(6周)的效果。结果显示,较长间隔后的临床肿瘤反应更好(71.7%对53.1%),肿瘤阳性和病理退缩率更高(26%对10.3%)。因此,放化疗与手术之间设定了6周的间隔,以平衡肿瘤学结果与手术复杂性。然而,最近的几项回顾性研究报告称,将间隔延长至8周甚至12周以上可能会导致肿瘤降期和病理完全缓解率显著提高。据一些报告称,这反过来可能会改善总生存期和无病生存期,而不会增加手术难度或并发症。这项工作回顾了关于不同间隔效果的数据,这些数据大多来自使用多种治疗方案的回顾性分析。目前正在进行前瞻性随机试验。